| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Moisés Mercado, Etual Espinosa, Claudia Ramíre. Current status and future directions of pharmacological therapy for acromegaly. Minerva endocrinologica. vol 41. issue 3. 2017-06-23. PMID:26485036. |
acromegaly can be approached pharmacologically by inhibiting gh secretion by the tumor (somatostatin analogues, dopamine agonists) or by antagonizing gh actions at its target tissues (gh receptor antagonists). |
2017-06-23 |
2023-08-13 |
Not clear |
| Václav Hán. [Current and future therapy of acromegaly]. Vnitrni lekarstvi. vol 62. issue 9 Suppl 3. 2017-06-22. PMID:27734694. |
octreotide in capsules, cam2029, somatoprim, atl1103).key words: acromegaly - cabergoline - new drugs - pegvisomant - somatostatin analogs - therapy. |
2017-06-22 |
2023-08-13 |
Not clear |
| Ansgar Heck, Kyrre E Emblem, Olivera Casar-Borota, Geir Ringstad, Jens Bollersle. MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly. Endocrine. vol 53. issue 1. 2017-06-16. PMID:26615593. |
mri t2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly. |
2017-06-16 |
2023-08-13 |
Not clear |
| Eric L Schneider, Jeff Henise, Ralph Reid, Gary W Ashley, Daniel V Sant. Subcutaneously Administered Self-Cleaving Hydrogel-Octreotide Conjugates Provide Very Long-Acting Octreotide. Bioconjugate chemistry. vol 27. issue 7. 2017-06-12. PMID:27253622. |
we developed a long-acting drug-delivery system that supports subcutaneous administration of the peptidic somatostatin agonist octreotide-a blockbuster drug used to treat acromegaly and neuroendocrine tumors. |
2017-06-12 |
2023-08-13 |
rat |
| Susan L Samso. Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR. Drugs. vol 76. issue 13. 2017-06-01. PMID:27473537. |
pasireotide (signifor(®)) long-acting release (lar) is a next-generation somatostatin receptor ligand (srl) approved for treatment of patients with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option. |
2017-06-01 |
2023-08-13 |
human |
| Alessandra Casagrande, Marcello D Bronstein, Raquel S Jallad, Aline B Moraes, Paula C L Elias, Margaret Castro, Mauro A Czepielewski, Artur Boschi, Antonio Ribeiro-Oliveira, Junia R O L Schweizer, Lucio Vilar, Debora M Nazato, Mônica R Gadelha, Julio Abucha. Long-Term Remission of Acromegaly after Octreotide Withdrawal Is an Uncommon and Frequently Unsustainable Event. Neuroendocrinology. vol 104. issue 3. 2017-05-08. PMID:27161443. |
long-term remission of acromegaly after somatostatin analog withdrawal has been reported in 18-42% of patients in studies with a relatively small number of patients using different inclusion and remission criteria. |
2017-05-08 |
2023-08-13 |
Not clear |
| S Yarman, G Y Yalın, S C Dogansen, B Canbaz, S Tanrıkulu, F Akyu. Double benefit of long-acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis. Journal of clinical pharmacy and therapeutics. vol 41. issue 5. 2017-04-26. PMID:27380906. |
double benefit of long-acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis. |
2017-04-26 |
2023-08-13 |
Not clear |
| S Yarman, G Y Yalın, S C Dogansen, B Canbaz, S Tanrıkulu, F Akyu. Double benefit of long-acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis. Journal of clinical pharmacy and therapeutics. vol 41. issue 5. 2017-04-26. PMID:27380906. |
somatostatin analogs control gh/igf-1 excess in acromegaly. |
2017-04-26 |
2023-08-13 |
Not clear |
| H Alibas, D Gogas Yavuz, P Kahraman Koytak, M Uygur, T Tanridag, K Ulu. Peripheral nervous system assessment in acromegaly patients under somatostatin analogue therapy. Journal of endocrinological investigation. vol 40. issue 1. 2017-04-25. PMID:27484912. |
peripheral nervous system assessment in acromegaly patients under somatostatin analogue therapy. |
2017-04-25 |
2023-08-13 |
Not clear |
| H Alibas, D Gogas Yavuz, P Kahraman Koytak, M Uygur, T Tanridag, K Ulu. Peripheral nervous system assessment in acromegaly patients under somatostatin analogue therapy. Journal of endocrinological investigation. vol 40. issue 1. 2017-04-25. PMID:27484912. |
in the present study, we aimed to examine pns of acromegaly patients under somatostatin analogue (ssa) therapy. |
2017-04-25 |
2023-08-13 |
Not clear |
| Przemysław Witek, Sławomir Mucha, Marek Ruchał. Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly. Endokrynologia Polska. vol 67. issue 6. 2017-04-20. PMID:28042650. |
despite the known importance of somatostatin analogues (ssas) in the treatment of acromegaly, patient satisfaction leading to preferences for specific ssas have received little attention so far. |
2017-04-20 |
2023-08-13 |
Not clear |
| b' Monica Livia Gheorghiu, Simona G\\xc4\\x83loiu, M\\xc4\\x83d\\xc4\\x83lina Vintil\\xc4\\x83, Mariana Purice, Dan Hortopan, Anda Dumitra\\xc5\\x9fcu, Mihail Coculescu, C\\xc4\\x83t\\xc4\\x83lina Poian\\xc4\\x8. Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center. Hormones (Athens, Greece). vol 15. issue 2. 2017-04-17. PMID:27376425.' |
beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a romanian tertiary care center. |
2017-04-17 |
2023-08-13 |
Not clear |
| b' Monica Livia Gheorghiu, Simona G\\xc4\\x83loiu, M\\xc4\\x83d\\xc4\\x83lina Vintil\\xc4\\x83, Mariana Purice, Dan Hortopan, Anda Dumitra\\xc5\\x9fcu, Mihail Coculescu, C\\xc4\\x83t\\xc4\\x83lina Poian\\xc4\\x8. Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center. Hormones (Athens, Greece). vol 15. issue 2. 2017-04-17. PMID:27376425.' |
somatostatin analogs (ssa) are now considered standard therapy for acromegaly, as primary or adjunctive treatment after pituitary surgery. |
2017-04-17 |
2023-08-13 |
Not clear |
| Natalia Bożena Zawada, Jolanta Kunert-Radek, Marek Pawlikowski, Hanna Pisarek, Maciej Rade. An evaluation of the effects of somatostatin analogue therapy in non-functioning pituitary adenomas in comparison to acromegaly. Endokrynologia Polska. vol 67. issue 3. 2017-04-07. PMID:27345147. |
an evaluation of the effects of somatostatin analogue therapy in non-functioning pituitary adenomas in comparison to acromegaly. |
2017-04-07 |
2023-08-13 |
Not clear |
| Natalia Bożena Zawada, Jolanta Kunert-Radek, Marek Pawlikowski, Hanna Pisarek, Maciej Rade. An evaluation of the effects of somatostatin analogue therapy in non-functioning pituitary adenomas in comparison to acromegaly. Endokrynologia Polska. vol 67. issue 3. 2017-04-07. PMID:27345147. |
recent data suggest that somatostatin analogues (ssa), so important in the pharmacotherapy of acromegaly, can also be effective in the management of nfpa. |
2017-04-07 |
2023-08-13 |
Not clear |
| Leila Warszawski, Leandro Kasuki, Rodrigo Sá, Cintia Marques Dos Santos Silva, Isabela Volschan, Ilan Gottlieb, Roberto Coury Pedrosa, Mônica R Gadelh. Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. Pituitary. vol 19. issue 6. 2017-04-05. PMID:27591859. |
low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. |
2017-04-05 |
2023-08-13 |
Not clear |
| Julie M Silverstei. Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly. Pituitary. vol 19. issue 5. 2017-04-04. PMID:27405306. |
pasireotide is a new-generation, multireceptor-targeted somatostatin receptor ligand approved for cd (subcutaneous [sc] injection formulation) and acromegaly (long-acting release [lar] formulation). |
2017-04-04 |
2023-08-13 |
Not clear |
| Babak Torabi Sagvand, Shafaq Khairi, Arezoo Haghshenas, Brooke Swearingen, Nicholas A Tritos, Karen K Miller, Anne Klibanski, Lisa B Nachtigal. Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center. Pituitary. vol 19. issue 4. 2017-03-22. PMID:27155600. |
long-acting somatostatin analogs are one of the main classes of medical therapy used for acromegaly and most patients require ongoing treatment. |
2017-03-22 |
2023-08-13 |
Not clear |
| Annamaria Colao, Renata S Auriemma, Rosario Pivonello, Leandro Kasuki, Mônica R Gadelh. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary. vol 19. issue 3. 2017-03-22. PMID:26519143. |
interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. |
2017-03-22 |
2023-08-13 |
Not clear |
| Annamaria Colao, Renata S Auriemma, Rosario Pivonello, Leandro Kasuki, Mônica R Gadelh. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary. vol 19. issue 3. 2017-03-22. PMID:26519143. |
the somatostatin analogues octreotide lar and lanreotide autogel have been evaluated for the treatment of acromegaly in numerous clinical trials, with considerable heterogeneity in reported biochemical response rates. |
2017-03-22 |
2023-08-13 |
Not clear |